Mark E. Neumann is a journalist who writes for Healio, covering a wide range of topics in the medical field. His articles focus on research studies, clinical trials, and developments in healthcare, with a particular emphasis on kidney disease, organ transplantation, and pharmaceutical advancements.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Mark E. Neumann’s coverage primarily focuses on healthcare and pharmaceutical topics, particularly kidney health and cancer care. His work heavily relies on data citations, indicating a preference for pitches supported by robust data or studies.
Given the extensive use of data in his articles, Mark would likely welcome pitches that present new research findings or clinical insights related to kidney health, cancer treatment, and associated pharmaceutical developments. Sources who can provide expert commentary based on recent scientific studies in these fields may also be well-received.
While Mark's geographic focus is not specified, it's important to note that the topics he covers are of global significance within the medical community. Therefore, relevant information from any location could potentially capture his interest if it contributes to advancements in understanding kidney health and cancer care.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Mark E. Neumann, Gina Brockenbrough
Among older adults participating in the Systolic Blood Pressure Intervention Trial, a low eGFR without albuminuria was associated with a higher mortality rate but not with increased risk of cardiovascular events, results showed.
By: Gina Brockenbrough, Mark E. Neumann
Patients with advanced chronic kidney disease may benefit from angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker use, but the antihypertensive agents may not reduce mortality risk, a retrospective analysis shows.
By: Gina Brockenbrough, Mark E. Neumann
A survey among patients and home dialysis nurses indicated that noise levels and setup time were key issues when using automated peritoneal dialysis machines.
By: Gina Brockenbrough, Mark E. Neumann
During a 20-year period, patients with end-stage kidney disease treated with hemodialysis saw a reduction in mortality worldwide, study results show. The biggest gain in survival was among patients the United States.
By: Mark E. Neumann, Gina Brockenbrough
Older adults with end-stage kidney disease had “modest gains” in life expectancy by starting on dialysis vs. choosing continuing medical management but spent less time at home, results from study show.
By: Gina Brockenbrough, Mark E. Neumann
Use of explainable machine learning combined with an AI classifier can aid health care providers in making accurate diagnoses and identifying root causes of chronic kidney disease at early stages, research data show.
By: Mark E. Neumann, Gina Brockenbrough
Sources of Healio | Nephrology News & Issues have made it clear that the explosive growth in the number of patients with end-stage kidney disease that join Medicare Advantage plans has overwhelmed everyone — payers and providers alike.
By: Mark E. Neumann, Gina Brockenbrough
The American Society of Transplantation has asked CMS to delay up to a year the launch of a 6-year demonstration aimed at increasing kidney transplants and improvements in graft survival.
By: Gina Brockenbrough, Mark E. Neumann
After 35 years, I am stepping down as editor-in-chief for Healio | Nephrology News & Issues. Retirement awaits, but I have pledged to myself to keep active.
By: Gina Brockenbrough, Mark E. Neumann
“The historic underfunding of the ESRD payment system has created disincentives for the development of new drugs, biologicals, devices and innovative treatment options ... ”
(833) 317-6278 
